“The existing situation has exposed some structural weaknesses within the EU’s medicines source chain along with a higher dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides stated. She proposed that supply chain challenges be dealt with in an EU pharmaceutical approach predicted to get released by